Revenue: As of FY2025 Q1, the actual value is USD 842 K.

EPS: As of FY2025 Q1, the actual value is USD -0.11.

EBIT: As of FY2025 Q1, the actual value is USD -20.81 M.

Segment Revenue

• Total Revenue: Quantum-Si reported first quarter 2025 revenue of $842,000, an 84% increase over the first quarter of 2024.

Operational Metrics

• Gross Profit: $486,000 with a gross margin of 58%.
• Total Operating Expenses: $25.6 million in Q1 2025, compared to $23.6 million in Q1 2024.
• Adjusted Total Operating Expenses: $22.9 million in Q1 2025, compared to $21.9 million in Q1 2024.
• Net Loss: $19.2 million in Q1 2025, compared to $19.5 million in Q1 2024.
• Adjusted EBITDA: - $21.5 million in Q1 2025, compared to - $20.5 million in Q1 2024.

Cash Flow

• Cash and Cash Equivalents: As of March 31, 2025, the Company’s cash and cash equivalents and investments in marketable securities were $232.6 million.

Unique Metrics

• Product Revenue: $808,000 in Q1 2025, compared to $428,000 in Q1 2024.
• Service Revenue: $34,000 in Q1 2025, compared to $29,000 in Q1 2024.

Outlook / Guidance

Quantum-Si reaffirms its cash runway into the second half of 2027 and remains on track for the Q3 2025 launch of its version 4 Sequencing Kit. The company is optimistic about opportunities in pharma and biotech markets, as well as internationally, despite challenges in the U.S. life sciences market.